Natera, Inc.

NASDAQ:NTRA

Medical - Diagnostics & Research

Healthcare
$289.50 +0.98%

+$2.23 today

Market cap
$41.98B
Beta
1.54
P/E (TTM)
-143.0
EPS (TTM)
-$1.60
52W Low $131.81High $256.36

Volume 1.96M

Average 1.41M

NTRA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Natera, Inc.NASDAQ: NTRA

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q2 FY2026 stock-based compensation of $103.1M rose 10.4% year over year, behind the +21.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.4% from the prior quarter. Over 3 fiscal years it compounded at +32.5% a year.

Context

  • Stock-based compensation amounted to 15.4% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.4% toward the trailing-twelve-month pace of +21.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$103.1M+8.4% QoQ
Last fiscal yearDec 2025
$354.4M+29.1% YoY
LTMJun 2026
$381.42M+21.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.4%——
1 year+29.1%——
3-year CAGR+32.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
354.4M USD
Year-over-year change
+29.1%
4-year CAGR
+32.4%

Stock-Based Compensation vs competitors

How NTRA compares with its peers on the latest reported figures

  • NTRA's LTM Jun 2026 stock-based compensation of $381.42M is the largest of the 8 companies compared; the peer median is $29.03M.
  • Its year-over-year change of +21.6% is the 2nd highest of 7, against a peer median of -18.2%.
  • Stock-based compensation amounts to 14.1% of revenue for NTRA, versus a peer median of 8.6%.
NTRA Competitors Peer median
Stock-Based Compensation for NTRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$381.42M +21.6%+32.5%14.1%
VCYTVeracyte, Inc.LTM Jun 2026$48.51M +20.3%+17.7%8.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$35.7M +95.3%-8.5%7.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$29.03M -33.3%+6.6%9.1%
BLLNBillionToOne, Inc.LTM Jun 2026$25.54M ——6.4%
PSNLPersonalis, Inc.LTM Mar 2026$9.76M -4.5%-21.4%15.1%
SERASera Prognostics, Inc.LTM Mar 2026$4.45M -34.7%+0.4%7810.5%
Peer median (excluding NTRA) $29.03M-18.2%-1.1%8.6%

Competitors are the stored peer set for NTRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(471.72M)(547.8M)(434.8M)(190.43M)(208.16M)
Depreciation & Amortization11.25M16.7M24.1M30.97M43.48M
Deferred Income Tax00000
Stock-Based Compensation115.22M152.38M191.81M274.43M354.4M
Change in Working Capital(45.6M)(83.15M)(47.95M)2.14M10.05M
Accounts Receivables(43.51M)(122.31M)(33.9M)(35.88M)20.75M
Inventory(6.88M)(8.5M)(5.35M)(3.99M)(20.87M)
Accounts Payables19.22M5.46M(15.46M)13.21M753K
Other Working Capital(14.44M)42.2M6.76M28.79M9.41M
Other Non-Cash Items55.61M30.36M19.89M18.55M15.53M
Operating Cash Flow(335.24M)(431.5M)(246.96M)135.66M215.3M
Capital Expenditures(41.03M)(47.7M)(39.2M)(66.42M)(106.19M)
Acquisitions (Net)0000(16.02M)
Purchases of Investments(876.1M)(86.95M)(98.3M)(124.68M)0
Sales of Investments720.49M464.98M306M339.22M23M
Other Investing Activities(8.56M)00(10.5M)0
Investing Cash Flow(205.19M)330.34M168.5M137.62M(132.21M)
Debt Repayment030M0(82K)0
Common Stock Issued576.19M452.64M254.46M30.29M47.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow576.19M482.64M254.46M30.2M47.46M
Effect of Forex Changes00000
Net Change in Cash35.76M381.48M176M303.49M130.55M
Free Cash Flow(376.27M)(479.2M)(286.15M)69.24M109.11M

Natera, Inc.

NASDAQ:NTRA

Intrinsic Alpha fair value

Locked

Current Price

$289.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.